Back

Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension

30 August 2026 (14:00 - 14:15)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Luke Joseph Laffin

Cleveland Clinic, Cleveland (United States of America)

4 More presentations in this session

Presentation thumbnail
Effects of finerenone in patients with hypertensive nephropathy
Professor H. Heerspink (Groningen, NL)
Slides Video
Presentation thumbnail
Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies
Doctor J. Wilson (London, GB)
Slides Video
Presentation thumbnail
Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
Professor C. Lam (Singapore, SG)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 14:00 CET
You may be interested in
thumbnail
Congress Presentation
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
30 August 2025
thumbnail
Congress Presentation
Safety and efficacy of treatment with mavacamten for up to 5 years in patients with obstructive hypertrophic cardiomyopathy: final results from MAVA-LTE
29 August 2026
thumbnail
Congress Presentation
Duration of blood pressure treatment and risk of major cardiovascular events
31 August 2025
thumbnail
Congress Presentation
RNA interference therapy targeting hepatic angiotensinogen for the treatment of hypertension and cardiovascular disease: a first-in-human and proof-of-concept study
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources